Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Response
100%
Multiple Sclerosis
100%
Minocycline
100%
Immune Alterations
100%
Magnetic Resonance Imaging
57%
Gadolinium
28%
Imaging Results
28%
In Vitro Activity
14%
Interleukin-12 (IL-12)
14%
Small Clinical Trials
14%
Annualized Relapse Rate
14%
Baseline Period
14%
Immunomodulatory Activity
14%
Relapsing-remitting multiple Sclerosis
14%
Interleukin-12 Receptor
14%
Pro-inflammatory Interleukins
14%
Half-dose
14%
Neuroprotective Activity
14%
Immunological Changes
14%
Immune Molecules
14%
P40 Subunit
14%
Soluble Vascular Cell Adhesion molecule-1
14%
Nase
14%
Gadolinium-enhancing Lesions
14%
Medicine and Dentistry
Multiple Sclerosis
100%
Minocycline
100%
Magnetic Resonance Imaging
57%
Gadolinium
42%
In Vitro
14%
Neuroprotective Agent
14%
Recurrence Risk
14%
Interleukin 12
14%
Antiserum
14%
Interleukin 12 Receptor
14%
Vascular Cell Adhesion Molecule 1
14%
Neuroscience
Multiple Sclerosis
100%
Minocycline
100%
Magnetic Resonance Imaging
57%
In Vitro
14%
Neuroprotective Agent
14%
Interleukin 12
14%
Relapsing Remitting Multiple Sclerosis
14%
Antiserum
14%
VCAM-1
14%
Interleukin 12 Receptor
14%
Immunology and Microbiology
Magnetic Resonance Imaging
100%
Multiple Sclerosis
100%
Interleukin 12
50%
VCAM-1
25%
Antiserum
25%
Relapsing Remitting Multiple Sclerosis
25%